NCT00152243View on ClinicalTrials.gov

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)

PHASE3CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

March 31, 2006

Study Completion Date

August 31, 2007

Conditions

Gastric Cancer

Interventions

DRUG

UFT (uracil, tegafur)

uracil-tegafur 360 mg per square meter per day orally 16 months

PROCEDURE

Surgery alone

Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.

Trial Locations (1)

Unknown

Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koto-ku

All Listed Sponsors

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00152243 - A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC) | Biotech Hunter | Biotech Hunter